Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prime Medicine, Inc. (PRME : NSDQ)

• Company Description    Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass. Number of Employees: 146

• Price / Volume Information    Yesterday's Closing Price: $3.47 Daily Weekly Monthly 20 Day Moving Average: 2,563,798 shares Shares Outstanding: 181.38 (millions) Market Capitalization: $629.38 (millions) Beta: 2.34 52 Week High: $6.94 52 Week Low: $2.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.44% 10.03% 12 Week 9.81% 6.70% Year To Date 0.00% -10.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 First Street - Cambridge,MA 02141 USA ph: 617-465-0013 fax: - hannah.deresiewicz@sternir.com https://primemedicine.com

• General Corporate Information    Officers Allan Reine - Chief Executive Officer and Chief Financial Office Carman Alenson - Chief Accounting Officer Thomas Cahill - Director Wendy Chung - Director Kaye Foster - Director Peer Information Prime Medicine, Inc. (CORR.) Prime Medicine, Inc. (RSPI) Prime Medicine, Inc. (CGXP) Prime Medicine, Inc. (BGEN) Prime Medicine, Inc. (GTBP) Prime Medicine, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74168J101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/06/26 Share - Related Items Shares Outstanding: 181.38 Most Recent Split Date: (:1) Beta: 2.34 Market Capitalization: $629.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.74 Price/Cash Flow: - Price / Sales: 154.52 EPS Growth vs. Year Ago Period: 41.46% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: 3.50% vs. Previous Quarter: 34.81% ROE 06/30/26 - -188.27 03/31/26 - -188.82 12/31/25 - -178.60 ROA 06/30/26 - -59.11 03/31/26 - -60.97 12/31/25 - -60.27 Current Ratio 06/30/26 - 3.05 03/31/26 - 3.80 12/31/25 - 4.84 Quick Ratio 06/30/26 - 3.05 03/31/26 - 3.80 12/31/25 - 4.84 Operating Margin 06/30/26 - -4,613.11 03/31/26 - -4,917.55 12/31/25 - -4,342.44 Net Margin 06/30/26 - -4,613.11 03/31/26 - -4,917.55 12/31/25 - -4,342.44 Pre-Tax Margin 06/30/26 - -4,613.11 03/31/26 - -4,917.55 12/31/25 - -4,342.44 Book Value 06/30/26 - 0.22 03/31/26 - 0.42 12/31/25 - 0.67 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©